These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 28524118)

  • 41.
    Umbricht CA; Benešová M; Schmid RM; Türler A; Schibli R; van der Meulen NP; Müller C
    EJNMMI Res; 2017 Dec; 7(1):9. PubMed ID: 28102507
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Radiopharmaceuticals for the Diagnosis and Therapy of Neuroendocrine Differentiated Prostate Cancer.
    Giovacchini G; Giovannini E; Riondato M; Ciarmiello A
    Curr Radiopharm; 2017; 10(1):6-15. PubMed ID: 28034291
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Development of a [177Lu]BPAMD labeling kit and an automated synthesis module for routine bone targeted endoradiotherapy.
    Meckel M; Nauth A; Timpe J; Zhernosekov K; Puranik AD; Baum RP; Rösch F
    Cancer Biother Radiopharm; 2015 Mar; 30(2):94-9. PubMed ID: 25714451
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Phosphinic acid functionalized polyazacycloalkane chelators for radiodiagnostics and radiotherapeutics: unique characteristics and applications.
    Notni J; Šimeček J; Wester HJ
    ChemMedChem; 2014 Jun; 9(6):1107-15. PubMed ID: 24700633
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Development and Pharmacological Evaluation of New Bone-Targeted (99m)Tc-Radiolabeled Bisphosphonates.
    Makris G; Tseligka ED; Pirmettis I; Papadopoulos MS; Vizirianakis IS; Papagiannopoulou D
    Mol Pharm; 2016 Jul; 13(7):2301-17. PubMed ID: 27170456
    [TBL] [Abstract][Full Text] [Related]  

  • 46. 68Ga-DOTA-Tyr3-octreotide PET for assessing response to somatostatin-receptor-mediated radionuclide therapy.
    Gabriel M; Oberauer A; Dobrozemsky G; Decristoforo C; Putzer D; Kendler D; Uprimny C; Kovacs P; Bale R; Virgolini IJ
    J Nucl Med; 2009 Sep; 50(9):1427-34. PubMed ID: 19690033
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A triazacyclononane-based bifunctional phosphinate ligand for the preparation of multimeric 68Ga tracers for positron emission tomography.
    Notni J; Hermann P; Havlícková J; Kotek J; Kubícek V; Plutnar J; Loktionova N; Riss PJ; Rösch F; Lukes I
    Chemistry; 2010 Jun; 16(24):7174-85. PubMed ID: 20461824
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pretherapeutic 68Ga-PSMA-617 PET May Indicate the Dosimetry of 177Lu-PSMA-617 and 177Lu-EB-PSMA-617 in Main Organs and Tumor Lesions.
    Wang J; Zang J; Wang H; Liu Q; Li F; Lin Y; Huo L; Jacobson O; Niu G; Fan X; Zhu Z; Chen X
    Clin Nucl Med; 2019 Jun; 44(6):431-438. PubMed ID: 30985422
    [TBL] [Abstract][Full Text] [Related]  

  • 49. 68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT.
    Gabriel M; Decristoforo C; Kendler D; Dobrozemsky G; Heute D; Uprimny C; Kovacs P; Von Guggenberg E; Bale R; Virgolini IJ
    J Nucl Med; 2007 Apr; 48(4):508-18. PubMed ID: 17401086
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Preclinical comparison of Al18F- and 68Ga-labeled gastrin-releasing peptide receptor antagonists for PET imaging of prostate cancer.
    Chatalic KL; Franssen GM; van Weerden WM; McBride WJ; Laverman P; de Blois E; Hajjaj B; Brunel L; Goldenberg DM; Fehrentz JA; Martinez J; Boerman OC; de Jong M
    J Nucl Med; 2014 Dec; 55(12):2050-6. PubMed ID: 25413139
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The Search for an Alternative to [
    Waldmann CM; Stuparu AD; van Dam RM; Slavik R
    Theranostics; 2019; 9(5):1336-1347. PubMed ID: 30867834
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Clinical Translation and First In-Human Use of [
    Eppard E; de la Fuente A; Benešová M; Khawar A; Bundschuh RA; Gärtner FC; Kreppel B; Kopka K; Essler M; Rösch F
    Theranostics; 2017; 7(18):4359-4369. PubMed ID: 29158832
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Comparison of the diagnostic and prognostic values of 99mTc-MDP-planar bone scintigraphy, 131I-SPECT/CT and 18F-FDG-PET/CT for the detection of bone metastases from differentiated thyroid cancer.
    Qiu ZL; Xue YL; Song HJ; Luo QY
    Nucl Med Commun; 2012 Dec; 33(12):1232-42. PubMed ID: 23111353
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Value of
    Zhang S; Wang L; Wang T; Xing HQ; Huo L; Li F
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2018 Dec; 40(6):757-764. PubMed ID: 30606385
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Macrocyclic complexes of scandium radionuclides as precursors for diagnostic and therapeutic radiopharmaceuticals.
    Majkowska-Pilip A; Bilewicz A
    J Inorg Biochem; 2011 Feb; 105(2):313-20. PubMed ID: 21194633
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Convenient preparation of 68Ga-based PET-radiopharmaceuticals at room temperature.
    Velikyan I; Maecke H; Langstrom B
    Bioconjug Chem; 2008 Feb; 19(2):569-73. PubMed ID: 18205327
    [TBL] [Abstract][Full Text] [Related]  

  • 57.
    Jain A; Mathur A; Pandey U; Sarma HD; Dash A
    Bioorg Med Chem Lett; 2016 Dec; 26(23):5785-5791. PubMed ID: 27793567
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The renaissance of the ⁶⁸Ge/⁶⁸Ga radionuclide generator initiates new developments in ⁶⁸Ga radiopharmaceutical chemistry.
    Roesch F; Riss PJ
    Curr Top Med Chem; 2010; 10(16):1633-68. PubMed ID: 20583984
    [TBL] [Abstract][Full Text] [Related]  

  • 59. (68)Ga-labeled DOTA-peptides and (68)Ga-labeled radiopharmaceuticals for positron emission tomography: current status of research, clinical applications, and future perspectives.
    Breeman WA; de Blois E; Sze Chan H; Konijnenberg M; Kwekkeboom DJ; Krenning EP
    Semin Nucl Med; 2011 Jul; 41(4):314-21. PubMed ID: 21624565
    [TBL] [Abstract][Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.